Biotechnology

Estrella Immunopharma unveils promising Phase 1 data for its next-gen T-cell therapy, but can it overcome a crowded market and its own financial hurdles?

Eli Lilly partners with China's Zonsen PepLib, betting on its novel peptide platforms to fuel the next wave of therapies in oncology and metabolism.

A new partnership aims to slash waste and streamline clinical trials, heralding a tech-driven transformation in the backbone of drug development.

Novo Nordisk exec Karin Conde-Knape joins Valo as CSO, signaling a major validation for AI's role in creating next-generation medicines.

As X4 Pharmaceuticals preps for a key investor summit, all eyes are on its pivotal trial for chronic neutropenia and the commercial fate of XOLREMDI®.

Promega's new diagnostic for KEYTRUDA gains NMPA approval, opening doors for targeted solid tumor therapy amid China's growing precision medicine market.

A next-gen immunotherapy enters trials, hoping its safer design can unlock the immune system and form a potent combo against advanced solid tumors.

Amid a relentless outbreak, Brazil launches a massive pilot program for the IXCHIQ® vaccine, a critical test for public health and global preparedness.

Pharming Group projects strong 2026 growth, fueling ambitious clinical programs for rare immunodeficiencies and mitochondrial diseases.

With strong 2025 results as a tailwind, Agilent's upcoming Q1 earnings report will test its ambitious guidance and signal trends for the life sciences industry.

Bolstered by a massive capital infusion and strong investor demand, Vaxcyte is set to accelerate its broad-spectrum vaccine pipeline against market leaders.

Bermuda insurer Relm adds C-suite leaders from AXIS and Zurich, signaling a strategic push to dominate insurance for AI, crypto, and space tech.

Death rates fall, but a new report reveals rising incidence and stark inequities. Can new drugs and AI reshape the future for all patients?

Beyond M&A, ACROBiosystems' bioSeedin summit redefines growth, connecting global capital with biotech innovation in a new era of strategic partnerships.

Praxis and SEQSTER expand their alliance, leveraging a powerful data platform to speed up development of new treatments for epilepsy and other CNS disorders.

Devonian appoints veteran CFO Dennis Turpin and corrects stock options, signaling a strategic shift as it aims to overcome financial hurdles and advance its pipeline.

With its largest fund yet, the firm is doubling down on breakthrough biotech and medtech, signaling strong investor faith in deep science innovation.

vTv Therapeutics shores up its finances with a deal worth up to $135M, sharpening its focus on a breakthrough Type 1 diabetes drug, cadisegliatin.

With a major Phase 3 trial now in Europe, Crystalys Therapeutics aims to fill a critical gap in gout care with a drug already proven in Asian markets.

Mwyngil Therapeutics starts clinical trials for a novel brain-penetrating drug, aiming to tackle neuroinflammation at its source in MS and Parkinson's.